Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Medicenna Therapeutics Corp reported promising results from its ABILITY-1 study, showcasing the potential of its MDNA11 Superkine to enhance cancer treatment, particularly in patients resistant to existing therapies. The company also highlighted a strong financial position with $30 million in cash and projected milestones for 2025, fueling investor confidence. These developments underscore Medicenna’s innovative approach and potential impact on the immunotherapy market.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
